Leerink Partners Sets Targets for Three Biotech Companies
Leerink Partners set price targets for Vera Therapeutics, Nektar Therapeutics and Connect Biopharma, while issuing ratings on two of the stocks.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires reports, citing ratings actions from Benzinga, that Leerink Partners set a $34.00-per-share price target for Vera Therapeutics. The firm also initiated coverage of the company with a Market Perform rating.
For Nektar Therapeutics, Leerink Partners announced a price target of $130.00 per share. The firm set a $4.00-per-share target for Connect Biopharma and assumed coverage with an Outperform rating.
why it matters
The update brings new analyst reference points for three biotechnology companies. Such reports can draw attention to the shares and provide additional information for market participants tracking Leerink Partners’ assessments.
instruments
sources
- Vera Therapeutics Price Target Announced at $34.00/Share by Leerink Partners — Dow Jones Newswires, 12 October 2026 at 12:32 UTC
- Nektar Therapeutics Price Target Announced at $130.00/Share by Leerink Partners — Dow Jones Newswires, 12 October 2026 at 12:30 UTC
- Connect Biopharma Price Target Announced at $4.00/Share by Leerink Partners — Dow Jones Newswires, 12 October 2026 at 12:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗